Intelligent Bio Solutions Inc.
INBS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INBS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INBS
Intelligent Bio Solutions Inc. (INBS) is a life sciences company developing a fingerprint sweat-based drug screening system, currently pursuing FDA 510(k) clearance for opiate detection while scaling manufacturing through a strategic partnership.
Key risk: Australian government grant repayment
Market Cap
$7.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Intelligent Bio Solutions Inc. (INBS) is a life sciences company developing a fingerprint sweat-based drug screening system, currently pursuing FDA 510(k) clearance for opiate detection while scaling manufacturing through a strategic partnership.
- Revenue was $1.06M for the three months ended March 31, 2026, up from $0.73M in the prior-year period [sec_mda · as of 2026-05-13].
- Cash and equivalents stood at $4.0M as of June 30, 2026 [latest reported financials].
- The company received European Patent EP3752831 in March 2026, its eighth European patent, covering fingerprint chemical analysis contextualization [sec_mda · as of 2026-05-13].
- A clinical study program for FDA 510(k) submission for codeine detection in fingerprint sweat commenced in early 2026 [sec_mda · as of 2026-05-13].
- First shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under a partnership with Syrma Johari MedTech Ltd. was received and deployed in February 2026 [sec_mda · as of 2026-05-13].
What works
- The company has secured eight European patents, strengthening its intellectual property around fingerprint sweat drug testing technology [sec_mda · as of 2026-05-13].
- A strategic manufacturing partnership with Syrma Johari MedTech Ltd. has been validated with the first shipment of readers, indicating scalable production capacity [sec_mda · as of 2026-05-13].
- Revenue grew 45% year-over-year for the three months ended March 31, 2026, suggesting increasing commercial traction [sec_mda · as of 2026-05-13].
What to weigh
- The company has a repayment obligation of $1.51M to the Australian Government related to a manufacturing facility grant, payable in installments [sec_mda · as of 2026-08-19].
- Development and regulatory expenses increased to $1.90M for the nine months ended March 31, 2026, reflecting ongoing costs for FDA submission and clinical trials [sec_mda · as of 2026-05-13].
- The company has a history of operating losses and has financed operations primarily through equity offerings, indicating reliance on external capital [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
European patent grant for fingerprint chemical analysis
“the Company announced it had received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume”
SEC MD&A · May 13, 2026
Manufacturing partnership shipment
“the successful receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd.”
SEC MD&A · May 13, 2026
Clinical study for FDA 510(k) submission
“the Company announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine”
SEC MD&A · May 13, 2026
Risks & what to watch (3)›
Key risks
- Australian government grant repayment — The company owes $1.51M to the Australian Government, payable in installments, creating a cash liability [sec_mda · as of 2026-08-19].
- Dependence on FDA clearance — The company's U.S. market entry for its drug screening system hinges on FDA 510(k) clearance, which is not yet obtained [sec_mda · as of 2026-05-13].
- Reliance on equity financing — Operations have been funded primarily through equity offerings, which may dilute shareholders if continued [sec_mda · as of 2026-05-13].
What to watch
- Progress and results of the clinical study for FDA 510(k) submission for codeine detection [sec_mda · as of 2026-05-13].
- Cash burn rate and any additional capital raises, given $4.0M cash as of June 30, 2026 [latest reported financials].
- Revenue growth trajectory and ability to scale manufacturing with Syrma Johari partnership [sec_mda · as of 2026-05-13].
- Repayment schedule and impact of the Australian Government grant liability [sec_mda · as of 2026-08-19].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Intelligent Bio Solutions Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Intelligent Bio Solutions Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$711K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 130,000 | $435K |
| alyeska investment group, l.p. | 37,956 | $127K |
| geode capital management, llc | 28,609 | $96K |
| vanguard capital management llc | 11,620 | $39K |
| vanguard fiduciary trust co | 3,958 | $13K |
| osaic holdings, inc. | 200 | $670 |
| curio wealth, llc | 200 | $669 |
Short Interest
as of May 20, 2026- % of float
- 2.5%
- Days to cover
- 0.5
- Shares short
- 54,635
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INBS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. (INBS) is a life sciences company developing a fingerprint sweat-based drug screening system, currently pursuing FDA 510(k) clearance for opiate detection while scaling manufacturing through a strategic partnership.
Who is the CEO of Intelligent Bio Solutions Inc.?
Mr. Harry Simeonidis is the chief executive officer of Intelligent Bio Solutions Inc. (INBS).
Where is Intelligent Bio Solutions Inc. headquartered?
Intelligent Bio Solutions Inc. (INBS) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.